skip to Main Content

Repurposing Metformin, Simvastatin and Digoxin as a Combination for Targeted Therapy for Pancreatic Ductal Adenocarcinoma

Repurposing Metformin, Simvastatin and Digoxin as a Combination for Targeted Therapy for Pancreatic Ductal Adenocarcinoma
Patients with pancreatic adenocarcinoma (PDAC) have a 5-year survival rate of 8%, the lowest of any cancer in the United States. Traditional chemotherapeutic regimens, such as gemcitabine- and fluorouracil-based regimens, often only prolong survival by months.

Effective precision targeted therapy is therefore urgently needed to substantially improve survival. In an effort to expedite approval and delivery of targeted therapy to patients, we utilized a platform to develop a novel combination of FDA approved drugs that would target pancreaticoduodenal homeobox1 (PDX1) and baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) utilizing super-promoters of the target genes to interrogate an FDA approved drug library.  Read more . . . 


Back To Top